Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016', provides an overview of the Charcot-Marie-Tooth Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Charcot-Marie-Tooth Disease and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Charcot-Marie-Tooth Disease - The report reviews pipeline therapeutics for Charcot-Marie-Tooth Disease by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Charcot-Marie-Tooth Disease therapeutics and enlists all their major and minor projects - The report assesses Charcot-Marie-Tooth Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Charcot-Marie-Tooth Disease Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Charcot-Marie-Tooth Disease - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Charcot-Marie-Tooth Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Charcot-Marie-Tooth Disease Overview 7 Therapeutics Development 8 Pipeline Products for Charcot-Marie-Tooth Disease - Overview 8 Pipeline Products for Charcot-Marie-Tooth Disease - Comparative Analysis 9 Charcot-Marie-Tooth Disease - Therapeutics under Development by Companies 10 Charcot-Marie-Tooth Disease - Therapeutics under Investigation by Universities/Institutes 11 Charcot-Marie-Tooth Disease - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Charcot-Marie-Tooth Disease - Products under Development by Companies 14 Charcot-Marie-Tooth Disease - Products under Investigation by Universities/Institutes 15 Charcot-Marie-Tooth Disease - Companies Involved in Therapeutics Development 16 Acetylon Pharmaceuticals, Inc. 16 Addex Therapeutics Ltd 17 Affectis Pharmaceuticals AG 18 Genzyme Corporation 19 InFlectis BioScience 20 Lead Discovery Center GmbH 21 PharmatrophiX, Inc. 22 Pharnext SAS 23 Charcot-Marie-Tooth Disease - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Combination Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 31 Drug Profiles 33 (baclofen + naltrexone + sorbitol) - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 ADX-71441 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 AFC-5128 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 IFB-088 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 LM-22B10 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecule to Inhibit Rab7 GTPase for Oncology, Neuropathy, Immunology, Neurodegenerative Diseases, Lipidoses and Charcot-Marie-Tooth Disease Type II - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecules for Charcot-Marie-Tooth Disease Type I A - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecules to Inhibit HDAC-6 for Immunology, Oncology and Genetic Disorders - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Small Molecules to Inhibit PMP22 for Charcot-Marie-Tooth Type 1 A - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Stem Cell Therapy to Activate PMP22 for Charcot-Marie-Tooth Disease Type 1A - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Charcot-Marie-Tooth Disease - Dormant Projects 47 Charcot-Marie-Tooth Disease - Product Development Milestones 48 Featured News & Press Releases 48 Apr 25, 2016: Pharnext Announces the Opening of the First U.S. Study Site for its PLEO-CMT International Pivotal Phase 3 Trial in Charcot-Marie-Tooth Disease Type 1A 48 Feb 16, 2016: Pharnext Supports the Fight Against Rare Diseases through Development of Pleotherapy-based Treatments 49 Jan 25, 2016: IFB-088 (Sephin1) receives orphan drug designation in the European Union for the treatment of Charcot-Marie-Tooth disease 49 Dec 15, 2015: Pharnext Initiates PLEO-CMT, an International Pivotal Phase 3 Trial, in Charcot-Marie-Tooth disease type 1A 50 Oct 27, 2015: FDA grants orphan drug designation to IFB-088 (Sephin1) for the treatment of Charcot-Marie-Tooth disease 51 Jun 30, 2015: Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 51 Jan 13, 2015: InFlectis BioScience banks €1.75m to realise the potential of IFB-088 drug candidate, a breakthrough therapeutic approach to treat neurodegenerative diseases 52 Dec 17, 2014: Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A through Two Peer-Reviewed Publications 52 Oct 21, 2014: Addex And The Charcot-Marie-Tooth Association Enter Collaboration To Advance ADX71441 In Charcot-Marie-Tooth 1A disorder 53 Jun 23, 2014: The EMA and FDA Grant Orphan Drug Designation to Pharnext's PXT-3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A 54 Oct 03, 2013: Addex ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease 55 Apr 24, 2013: Addex Receives Approval To Initiate Phase I First-In-man Clinical Study For ADX71441 55 Jan 22, 2013: Addex Receives Broad US Composition Of Matter Patent For ADX71441 56 Jan 07, 2013: Addex Therapeutics Announces Positive Data With ADX71441 In Pre-Clinical Transgenic Model Of Charcot-Marie-Tooth 1A Disease 57 Nov 22, 2011: Pharnext Completes Patient Recruitment For Phase II Study Of PXT3003 In Type 1A Charcot-Marie-Tooth Disease 57 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 60
List of Tables
Number of Products under Development for Charcot-Marie-Tooth Disease, H2 2016 8 Number of Products under Development for Charcot-Marie-Tooth Disease - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Charcot-Marie-Tooth Disease - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 16 Charcot-Marie-Tooth Disease - Pipeline by Addex Therapeutics Ltd, H2 2016 17 Charcot-Marie-Tooth Disease - Pipeline by Affectis Pharmaceuticals AG, H2 2016 18 Charcot-Marie-Tooth Disease - Pipeline by Genzyme Corporation, H2 2016 19 Charcot-Marie-Tooth Disease - Pipeline by InFlectis BioScience, H2 2016 20 Charcot-Marie-Tooth Disease - Pipeline by Lead Discovery Center GmbH, H2 2016 21 Charcot-Marie-Tooth Disease - Pipeline by PharmatrophiX, Inc., H2 2016 22 Charcot-Marie-Tooth Disease - Pipeline by Pharnext SAS, H2 2016 23 Assessment by Monotherapy Products, H2 2016 24 Assessment by Combination Products, H2 2016 25 Number of Products by Stage and Target, H2 2016 27 Number of Products by Stage and Mechanism of Action, H2 2016 29 Number of Products by Stage and Route of Administration, H2 2016 30 Number of Products by Stage and Molecule Type, H2 2016 32 Charcot-Marie-Tooth Disease - Dormant Projects, H2 2016 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.